On Tuesday, Pfizer and BioNTech announced they’re seeking Food and Drug Administration authorization for the first two doses of a planned three-dose Covid-19 vaccine regimen for children under 5 — the last age bracket remaining witout a Covid-19 vaccine. The agency also announced that it would convene its independent panel of vaccine experts on Feb. 15 to consider the data and make a recommendation to regulators. The Centers for Disease Control and Prevention’s advisers could quickly follow suit should the FDA grant the request, meaning these children could receive their first vaccines later this month. While many welcomed the new development, some pediatricians raised concerns that the companies were moving too quickly, before they had finished studying whether a third dose would provide the necessary protection to children.

Learn more about your ad choices. Visit megaphone.fm/adchoices